| Bioactivity | K882 (Compound 4e) is a Src inhibitor, with KD of 0.315 μM. K882 induces Apoptosis. K882 inhibits XIAP and Survivin. K882 inhibits the activation of PI3K/Akt/mTOR, Jak1/Stat3, Ras/MAPK signaling pathways. K882 shows anti-tumor activity against non-small cell lung cancer[1]. |
| Invitro | K882 (0.5-8 μM，24-72 h) 对 KRASG12C 突变 NCI-H358 细胞的增殖、迁移和侵袭表现出显著的抑制活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> K882 相关抗体: Cell Cycle Analysis[1] Cell Line: |
| In Vivo | K882 (25-100 mg/kg，腹腔注射，每天一次，31天) 抑制 NCI-H358 异种移植肿瘤小鼠模型中KRASG12C 突变型 NSCLC 异种移植瘤的生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C18H16N2O2 |
| Molar Mass | 292.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ma X, et al. Identification of a novel Src inhibitor K882 derived from quinazoline-based stilbenes with anti-NSCLC effect. Bioorg Chem. 2025 Mar;156:108185. |